Form 4: Arcutis Officer Sells Shares for Tax Obligations

Arcutis Biotherapeutics' EVP Chief Commercial Officer, Larry Todd Edwards, sold 2,052 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Larry Todd Edwards, EVP Chief Commercial Officer of Arcutis Biotherapeutics, Inc. (ARQT), sold 2,052 shares of common stock.
• The sale occurred on February 2, 2026, at a weighted average price of $25.4984 per share.
• The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted on January 12, 2024, with 25% vesting annually starting February 1, 2025.
• Following this transaction, Larry Todd Edwards beneficially owns 148,865 shares directly.
• This total includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025.
• The transaction was made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, and not indicative of a change in company fundamentals or insider sentiment.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates continued service and compensation for the reporting person.
• The transaction was executed under a Rule 10b5-1 plan, demonstrating pre-planned and compliant trading.

Negatives

• A sale of shares by an executive, even for tax purposes, reduces their direct ownership in the company.

Future Outlook

No explicit future outlook is provided beyond the established RSU vesting schedule.

Industry Context

StockSavvy.ai notes that routine insider sales for tax obligations related to RSU vesting are common across the biotechnology industry, particularly for executives whose compensation packages heavily feature equity. These transactions typically do not signal a change in management's outlook on the company's fundamentals.

Comparison to Industry Standards

• Routine tax-related sales by executives are standard practice across publicly traded companies, including those in the biotech sector like Amgen or Gilead Sciences, where equity compensation is prevalent.
• The volume of shares sold (2,052) is relatively small compared to the executive's total beneficial ownership (148,865 shares), which is typical for covering tax liabilities on vested equity rather than a significant divestment.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related sale, not a significant divestment.
• Employees: The RSU vesting and ESPP participation demonstrate ongoing employee equity compensation programs.

Next Steps

• Annual vesting of 25% of RSUs on February 1st of each year, beginning February 1, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of shares by an executive to cover tax obligations related to RSU vesting. Such transactions are common and generally do not reflect a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, insider trading, stock sale, RSU vesting, tax withholding, executive compensation, Larry Todd Edwards, 10b5-1 plan